NasdaqGM:TMDX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. More Details


Snowflake Analysis

Adequate balance sheet and fair value.


Similar Companies

Share Price & News

How has TransMedics Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TMDX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: TMDX's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

3.7%

TMDX

2.0%

US Medical Equipment

0.7%

US Market


1 Year Return

-14.5%

TMDX

19.1%

US Medical Equipment

22.2%

US Market

Return vs Industry: TMDX underperformed the US Medical Equipment industry which returned 19.4% over the past year.

Return vs Market: TMDX underperformed the US Market which returned 22.7% over the past year.


Shareholder returns

TMDXIndustryMarket
7 Day3.7%2.0%0.7%
30 Day27.1%5.6%11.8%
90 Day-11.1%6.3%8.6%
1 Year-14.5%-14.5%20.1%19.1%25.0%22.2%
3 Yearn/a75.3%70.8%49.4%39.5%
5 Yearn/a143.2%124.6%100.2%78.1%

Long-Term Price Volatility Vs. Market

How volatile is TransMedics Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is TransMedics Group undervalued compared to its fair value and its price relative to the market?

21.7%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: TMDX ($15.14) is trading below our estimate of fair value ($19.33)

Significantly Below Fair Value: TMDX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: TMDX is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: TMDX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TMDX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TMDX is good value based on its PB Ratio (3.8x) compared to the US Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is TransMedics Group forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

25.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TMDX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TMDX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TMDX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TMDX's revenue (69.2% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: TMDX's revenue (69.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TMDX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has TransMedics Group performed over the past 5 years?

-16.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TMDX is currently unprofitable.

Growing Profit Margin: TMDX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TMDX is unprofitable, and losses have increased over the past 5 years at a rate of 16.5% per year.

Accelerating Growth: Unable to compare TMDX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TMDX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.2%).


Return on Equity

High ROE: TMDX has a negative Return on Equity (-28.86%), as it is currently unprofitable.


Next Steps

Financial Health

How is TransMedics Group's financial position?


Financial Position Analysis

Short Term Liabilities: TMDX's short term assets ($154.1M) exceed its short term liabilities ($13.6M).

Long Term Liabilities: TMDX's short term assets ($154.1M) exceed its long term liabilities ($36.1M).


Debt to Equity History and Analysis

Debt Level: TMDX's debt to equity ratio (31.5%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if TMDX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TMDX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TMDX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is TransMedics Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TMDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TMDX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TMDX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TMDX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TMDX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average management tenure


CEO

Waleed Hassanein (52 yo)

22.33yrs

Tenure

US$3,159,298

Compensation

Dr. Waleed H. Hassanein, M.D. is the Founder of Transmedics Group, Inc. and has been its President, Chief Executive Officer and Director since August 1998. He Founded TransMedics, Inc. in August 1998 and h...


CEO Compensation Analysis

Compensation vs Market: Waleed's total compensation ($USD3.16M) is above average for companies of similar size in the US market ($USD1.79M).

Compensation vs Earnings: Waleed's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Waleed Hassanein
Founder22.33yrsUS$3.16m0.79%
$ 3.3m
Stephen Gordon
CFO. Treasurer & Secretary5.75yrsUS$491.92k0.068%
$ 281.1k
Tamer Khayal
Chief Commercial Officer14.92yrsUS$1.05m0.17%
$ 697.6k
John Carey
Vice President of Operations7.92yrsno data0.012%
$ 48.4k
Ike Okonkwo
Vice President of Finance & Accounting1.75yrsno datano data
Mark Anderson
Senior Director of Technology Development1.92yrsno datano data
Brian Thomson
Vice President of Human Resources2.25yrsno datano data

5.8yrs

Average Tenure

52yo

Average Age

Experienced Management: TMDX's management team is seasoned and experienced (5.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Waleed Hassanein
Founder22.33yrsUS$3.16m0.79%
$ 3.3m
Edwin Kania
Independent Director17.92yrsno data0.57%
$ 2.3m
James Tobin
Independent Chairman9.92yrsUS$62.01k1.6%
$ 6.6m
Edward Zavala
Member of Advisory Boardno datano datano data
Gayle Winters
Member of Advisory Boardno datano datano data
Ryszard Smolenski
Member of Advisory Boardno datano datano data
Bruce Rosengard
Member of Advisory Boardno datano datano data
Scott Solomon
Member of Advisory Boardno datano datano data
Robert Kormos
Member of Advisory Boardno datano datano data
Valluvan Jeevanandam
Member of Advisory Boardno datano datano data
José Núñez
Member of Advisory Boardno datano datano data
Edward Basile
Independent Director4.83yrsUS$39.17k0%
$ 0

13.9yrs

Average Tenure

67yo

Average Age

Experienced Board: TMDX's board of directors are seasoned and experienced ( 13.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.3%.


Top Shareholders

Company Information

TransMedics Group, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TransMedics Group, Inc.
  • Ticker: TMDX
  • Exchange: NasdaqGM
  • Founded: 1998
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$411.215m
  • Shares outstanding: 27.16m
  • Website: https://www.transmedics.com

Number of Employees


Location

  • TransMedics Group, Inc.
  • 200 Minuteman Road
  • Suite 302
  • Andover
  • Massachusetts
  • 1810
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TMDXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDMay 2019

Biography

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The c...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/02 23:18
End of Day Share Price2020/12/02 00:00
Earnings2020/09/30
Annual Earnings2019/12/28


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.